An interventional study of Continuous video-guided right-sided double-lumen tube and Conventional right-sided double-lumen tube in Right-sided Double-lumen Tube Positioning, Lung Isolation During Thoracoscopic Surgery and One-lung Ventilation, sponsored by Diansan Su. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Diansan Su · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 850 studies in Lung Neoplasms with a site in China — 376 open to participants now, 423 under way, 34 of them phase 3. Lung Neoplasms · China.
Among the 850 studies in Lung Neoplasms with a site in China, this one is the 65th largest by planned enrollment of the 590 interventional ones that give a count, is one of 92 that started in 2026, is one of 214 with no phase, reaches primary completion later than 242 of the 422 other live ones, and was the 825th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →376 of the 850 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:
Zhongnan Hospital · Sites in China
Ages 18+ · Healthy volunteers
Peking University First Hospital · Sites in China
Ages 18–75 · Healthy volunteers
West China Hospital · Sites in China
Ages 18–80
Xiamen University · Sites in China
Ages 18–80
AstraZeneca · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
850 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 139 · Phase 2 226 · Phase 3 77 · Phase 4 9
First in 1992; this study’s year is marked. 92 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 566 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 90 across the 590 interventional studies, 307 across the 259 observational. Of the 208 that completed or were terminated, 36 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
187 of 850 have an industry lead sponsor. The 10 most frequent:
Diansan Su is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Diansan Su has 1 study filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
118 of the studies in Lung Neoplasms with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607796Phase 3Zhou ChengzhiEfficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy | 2026-12 |
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT04841811Phase 3Guangdong Association of Clinical TrialsMDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH) | 2026-12-31 |
| NCT06598527Phase 3Yang HongStereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study | 2027-01-30 |
Add all 118 to your calendar (.ics) → With an account.
Among the 850 studies in Lung Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Right-sided double-lumen tubes are used for lung isolation during thoracoscopic surgery but can be difficult to position because of right bronchial anatomy. This multicenter randomized controlled trial will compare a continuous video-guided right-sided double-lumen tube with a conventional right-sided double-lumen tube in adult patients undergoing thoracoscopic surgery requiring right-sided lung isolation. The primary objective is to determine whether continuous video guidance increases the rate of successful initial right-sided double-lumen tube positioning. Secondary outcomes include positioning time, clinically relevant intraoperative tube displacement, rescue fiberoptic bronchoscopy, lung collapse quality, hypoxemia during one-lung ventilation, and airway-related complications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Continuous video-guided right-sided double-lumen tube
Device: Conventional right-sided double-lumen tube
Participants will receive a continuous video-guided right-sided double-lumen tube for lung isolation during thoracoscopic surgery. The device incorporates an integrated visualization system that provides continuous real-time airway visualization during tube positioning and intraoperative management.
Participants will receive a conventional right-sided double-lumen tube for lung isolation during thoracoscopic surgery according to standard clinical practice.
Number of participants with successful initial right-sided double-lumen tube positioning assessed by fiberoptic bronchoscopy
Successful initial positioning is defined as Grade 1 (optimal) or Grade 2 (acceptable) tube position at the first protocol-mandated fiberoptic bronchoscopic assessment before any bronchoscopic adjustment. Grade 3 (malposition) is considered unsuccessful. Successful positioning requires an acceptable bronchial cuff position, adequate alignment of the right upper-lobe ventilation slot with the right upper-lobe bronchial orifice, absence of clinically relevant right upper-lobe obstruction, and a patent bronchus intermedius without the need for further advancement, withdrawal, or rotation of the tube. Each participant will be classified as successful or unsuccessful.
Time frame: Intraoperatively, immediately after initial tube positioning and before initiation of one-lung ventilation.
Time to initial right-sided double-lumen tube positioning
Time in seconds from passage of the double-lumen tube through the vocal cords into the trachea until the anesthesiologist completes the initial right-sided bronchial positioning and no further tube advancement, withdrawal, or rotation is performed before the protocol-mandated fiberoptic bronchoscopic assessment.
Time frame: Periprocedural, during initial right-sided double-lumen tube positioning.
Number of unplanned intraoperative right-sided double-lumen tube repositioning events per participant
An event is defined as any unplanned advancement, withdrawal, rotation, or other repositioning of the right-sided double-lumen tube after satisfactory initial positioning has been confirmed. Minor positional changes not requiring intervention are not counted. For each repositioning event, the use of unplanned fiberoptic bronchoscopy for guidance or confirmation will be recorded as an event characteristic. The total number of repositioning events will be recorded for each participant.
Time frame: Intraoperatively, from confirmation of satisfactory initial tube position until completion of one-lung ventilation.
Quality of surgical lung collapse assessed by a 3-point surgeon-rated scale
The operating surgeon will assess the quality of surgical lung collapse using a predefined 3-point ordinal scale: 1 = poor, lung collapse is insufficient and interferes with surgical exposure or requires additional intervention; 2 = moderate, lung collapse is partially adequate with some interference with surgical exposure but without the need for additional intervention; and 3 = good, lung collapse is adequate and does not interfere with surgical exposure. Higher scores indicate better lung collapse.
Time frame: Intraoperatively, approximately 20 minutes after initiation of one-lung ventilation.
Number of hypoxemic episodes during one-lung ventilation per participant
A hypoxemic episode is defined as peripheral oxygen saturation (SpO₂) below 90% for at least 1 minute during one-lung ventilation, measured continuously by pulse oximetry. A new hypoxemic episode will be counted only after SpO₂ has recovered to 90% or above for at least 1 minute following the previous episode. The total number of hypoxemic episodes will be recorded for each participant.
Time frame: Intraoperatively, during one-lung ventilation.
Airway-related complications
Time frame: From airway instrumentation until 24 hours after surgery.
Plan to share: Undecided — The plan for sharing de-identified individual participant data has not yet been finalized. Any future data sharing will be considered in accordance with participant privacy, institutional data governance, applicable ethics requirements, and relevant study policies.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 5 months is below that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Diansan Su